Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 11/20 | 0.46 |
| ▸ | JAK2 | O60674 | 6/20 | 0.45 |
| ▸ | JAK1 | P23458 | 4/20 | 0.45 |
| ▸ | TYK2 | P29597 | 2/20 | 0.45 |
| ▸ | TTK | P33981 | 2/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | FLT4 | P35916 | 4/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14331666 | 0.91 | FLT4 (0.52) | JAK3JAK2JAK1TTKFLT4 | |
| SCHEMBL10206622 | 0.87 | ALK (0.44) | JAK3JAK2JAK1TYK2TTK | |
| SCHEMBL14331694 | 0.87 | NUAK1 (0.54) | JAK3JAK2JAK1TYK2TTK | |
| SCHEMBL10206154 | 0.87 | IGF1R (0.52) | JAK3JAK2JAK1TYK2AURKA | |
| SCHEMBL10205200 | 0.84 | ALK (0.47) | JAK3JAK2JAK1TYK2TTK | |
| SCHEMBL14331717 | 0.84 | IRAK4 (0.50) | JAK3JAK2JAK1TYK2TTK | |
| SCHEMBL10205197 | 0.83 | ALK (0.43) | JAK3JAK2JAK1TYK2TTK | |
| SCHEMBL10205897 | 0.82 | EGFR (0.46) | JAK3JAK2JAK1TTKIGF1R | |
| SCHEMBL10205181 | 0.82 | EGFR (0.45) | JAK3JAK2IGF1RINSRALK | |
| SCHEMBL10205220 | 0.80 | STAT6 (0.42) | JAK3FLT4KDRIGF1RINSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655358-B1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-11-19 | — | — | EP | disclosed |
| US-8546443-B2 | Benzylic oxindole pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| WO-2012085126-A1 | OXINDOLOPYRIMIDINE AS IGF1R RECEPTOR INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329771-A1 | BENZYLIC OXINDOLE PYRIMIDINES | MKI67, CCNI, CCNB1 | JAK3 1636/4885JAK2 241/4885JAK1 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.